BCAX Bicara Therapeutics Inc.
$17.48▲ +3.49%
Healthcare
Other
After hours
$17.48▲ +0.00%
Oct 27, 4:41 PM ET
Volume 609.3K
Avg Volume (10D) 879.2K
Key Metrics & Fundamentals
Market Cap
$1.16B
P/E Ratio
–
Div Yield
0.00%
52W Range
13.70 - 30.99
% vs 50 MA
-15.43%
% vs 200 MA
-18.05%
RSI-14
41.6
MACD Histogram
+0.2200
Beta (1Y vs SPY)
0.95
Free Cash Flow
-$44.27M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$59.91M
COGS
–
Operating Exp
$59.95M
Operating Income
-$59.95M
EBIT
-$59.95M
Pretax Income
-$55.38M
Net Income
-$55.44M
EPS (Diluted)
-0.82
Price & Volume History
Loading chart…
Recent News
Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book Value
Simply Wall St. · Oct 10, 2026 6:09 AM ET
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 5, 2026 8:30 AM ET
Pliant Therapeutics Appoints David Raben as Chief Medical Officer
MT Newswires · Sep 30, 2026 5:28 PM ET
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 3, 2026 8:30 AM ET
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul
Insider Monkey · Aug 19, 2026 9:56 AM ET
BMO Capital Initiates Bicara Therapeutics at Outperform
MT Newswires · Aug 19, 2026 6:10 AM ET
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 18, 2026 11:13 AM ET
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 14, 2026 8:30 AM ET
Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX)
Simply Wall St. · Aug 13, 2026 6:10 AM ET
Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing
MT Newswires · Aug 12, 2026 4:31 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See BCAX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.